MISSION Therapeutics develops therapies that enhance the removal of dysfunctional mitochondria to combat serious diseases.
MISSION Therapeutics has raised $13.3M in total funding. The most recent round was Venture - Series Unknown. The last funding was announced in October 2025.
MISSION Therapeutics's investors include Sofinnova Partners, SR One, Revelation Partners, Innovate UK, Michael J. Fox Foundation.
MISSION Therapeutics is headquartered in Cambridge, United Kingdom.
MISSION Therapeutics develops therapies that enhance the removal of dysfunctional mitochondria to combat serious diseases.
MISSION Therapeutics is at the Venture - Series Unknown stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"MISSION Therapeutics — Funding & Investors." VCBacked, October 15, 2025, https://www.vcbacked.co/company/mission-therapeutics. Accessed July 19, 2026.
VCBacked. (2025). MISSION Therapeutics — Funding & Investors. Retrieved July 19, 2026, from https://www.vcbacked.co/company/mission-therapeutics
{{cite web |title=MISSION Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/mission-therapeutics |website=VCBacked |access-date=July 19, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated